Abstracts

Abstracts should only be submitted through the website and in English. Abstracts cannot be submitted by fax, hard copy or e-mail.

Abstracts Submission

The presenting author has to be registered in order to be able to submit an abstract.

To submit an abstract the author will have to enter a specific code in the submission form.

Abstracts must be submitted electronically no later than midnight on 3 October 2019 (GMT).

Only the presenting author can submit an abstract. An abstract submitted by someone else might be refused.
Acknowledgement of receipt of the submission will be sent to the stated e-mail address.

The presenting author will receive all correspondence concerning the abstract and is responsible for informing co-authors of the status regarding the abstract.

In cases where the abstract is NOT accepted, participants will be contacted promptly and the registration fee fully reimbursed.

ABSTRACTS SELECTION PROCESS

Abstracts submitted for presentation will be reviewed by an international panel of experts.
The submitter will be notified of the acceptance or rejection of the abstract by December the 15th 2019 at the latest.
Abstracts can be selected for one or both of the following presentation formats:

  • Oral presentation
    The abstract is selected for oral presentation of 10-12 minutes within a dedicate session of the congress, as selected by the author.
  • Poster presentation:
    The abstract is selected for presentation in a poster format. Posters are grouped by topic and are displayed throughout the meeting in the dedicated poster room. Poster size: h = 1,50 x w = 0,90 m

If a selected presenting author cannot attend, he/she should assign a substitute and inform the congress secretariat of this replacement in due time.
Posters can be viewed by participants during lunch, coffee breaks and poster sessions.

Please note that a formal poster tour will be organised during the meeting.
All accepted abstracts will be published in the Conference Programme.

ABSTRACTS INSTRUCTIONS

  • Abstracts must be written in English.
  • Title maximum 200 characters.
  • Maximum 3,000 characters (including spaces and excluding title and contact information on authors).
  • There is a restriction of 20 co-authors for each abstract. If more co-authors have contributed, these should be referred to as Study Group. They can later be displayed on the poster or appropriately acknowledged during an oral, if applicable.
  • References and credits are not to be included in the abstract, nor subheadings or keywords.
  • Note that all subheadings in abstracts automatically be deleted by the programme committee.
  • It is the author’s responsibility to submit a correct abstract; if accepted any errors in spelling, grammar, or scientific fact will be reproduced as typed by the author.
  • Upon submission, indicate one of the following topics that best describes the content of the abstract: 
    • Emerging treatments & novel approaches in therapy
    • Newborn & pre-symptomatic screening
    • How SMN influences translation
    • Age-dependent responsiveness (symptomatic)
    • SMN independent pathways
    • Comprehensive management of SMA
    • The role of biomarkers in SMA
    • Others

ABSTRACTS FORMAT OF SUBMISSION

Submission reference number

Title:  maximum 200 character

Co-authors : maximum 20

Main topics:

  • Emerging treatments & novel approaches in therapy
  • Newborn & pre-symptomatic screening
  • How SMN influences translation
  • Age-dependent responsiveness (symptomatic)
  • SMN independent pathways
  • Comprehensive management of SMA
  • The role of biomarkers in SMA
  • Others

Text : 3 000 characters maximum

If you have any questions, contact Vanessa Christie-Brown

By email